RESUMO
The special AT-rich sequence binding-protein1 (SATB1) attracts excessive attention due to its high expression in a variety of malignancies. SATB1 reprograms chromatin and transcription profiles to promote tumor cell growth and invasion and inhibit apoptosis, leading to tumor progression and metastasis. Consistently, silencing SATB1 with small interfering RNA inhibits the growth and invasion of some kinds of tumors. In this review, we highlight recent progress in our understanding of the role of SATB1 as global regulator of gene expression during cancer development, and evaluate the potential of SATB1 as a molecular therapeutic target for cancers with aberrant SATB1 expression.
Assuntos
Proteínas de Ligação à Região de Interação com a Matriz/genética , Neoplasias/genética , Animais , Proliferação de Células/genética , Regulação Neoplásica da Expressão Gênica/genética , Humanos , Terapia de Alvo Molecular/métodosRESUMO
Sperm-associated antigen 9 (SPAG9) is a new member of cancer testis antigen and belongs to c-Jun NH2-terminal kinase (JNK) interacting protein (JIP) family. SPAG9 is highly expressed in a variety of tumors patients, and induces immune response in the host. SPAG9 regulates JNK and mitogen-activated protein kinases (MAPKs) signaling pathways which promote the growth, metastasis and drug resistance of tumors. In addition, SPAG9 modulates cell cycle progression and upregulates matrix metalloproteinases during the progression of tumors. Silencing SPAG9 expression could suppress the development of tumors. This review summarizes recent progress in our understanding of the emerging role of SPAG9 in tumorigenesis and highlights the potential of SPAG9 as a novel target for cancer diagnosis and therapy.